(Q46123265)

English

Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders

scientific article published on 12 February 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19214491

Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19214491

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

N Singh

1

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19214491

L Kumar

2

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19214491

R Meena

3

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19214491

T Velpandian

4

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19214491

publication date

12 February 2009

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19214491

European Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19214491

65

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19214491

6

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19214491

545-549

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19214491

https://scigraph.springernature.com/pub.10.1007/s00228-009-0621-z

0 references

Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19214491

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Genetic polymorphism of CYP2D6 in North Indian subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/19214491

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Genetics of the variable expression of CYP3A in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/19214491

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CYP3A phenotypes and genotypes in North Indians

1 reference

https://pubmed.ncbi.nlm.nih.gov/19214491

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chronic myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19214491

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development and validation of a simple liquid chromatographic method with ultraviolet detection for the determination of imatinib in biological samples

1 reference

https://pubmed.ncbi.nlm.nih.gov/19214491

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19214491

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19214491

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Imatinib mesylate--the new gold standard for treatment of chronic myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19214491

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Active transport of imatinib into and out of cells: implications for drug resistance

1 reference

https://pubmed.ncbi.nlm.nih.gov/19214491

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chronic myelogenous leukaemia (CML): an update

1 reference

https://pubmed.ncbi.nlm.nih.gov/19214491

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19214491

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical pharmacokinetics of imatinib

1 reference

https://pubmed.ncbi.nlm.nih.gov/19214491

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

hOCT 1 and resistance to imatinib

1 reference

https://pubmed.ncbi.nlm.nih.gov/19214491

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19214491

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate

1 reference

https://pubmed.ncbi.nlm.nih.gov/19214491

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19214491

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19214491

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate

1 reference

https://pubmed.ncbi.nlm.nih.gov/19214491

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/19214491

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/19214491

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00228-009-0621-Z

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19214491

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19214491

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46123265&oldid=2093458744"